Blog Archives

Worldwide more than 6.8 million people live with Inflammatory Bowel Disease (IBD) which is characterized by chronic inflammation of the gastrointestinal tract. The highest numbers of IBD patients are observed in North America and Europe with an estimated 2.2 million affected persons in North America and an estimated 0.3% of the European population suffering from

Because of the current situation with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the COVID-19 disease it is important to keep IBD patients out of clinics whenever possible. Nevertheless, tight monitoring of inflammation level in the gut is needed to deal with these chronic conditions. Calprotectin has proven to be an ideal

The use of fecal calprotectin (fCAL) in clinical routine is demonstrated beyond doubt. We now have extensive knowledge of its efficacy for IBD/IBS differentiation and IBD monitoring, as it has been shown to be an excellent surrogate biomarker for inflammatory status of the gut that correlates well with endoscopic activities (1). The key benefit of

At ECCO 2020, IBDoc® was again under the spotlight as 2 very interesting posters were presented. After 5 years of market presence, long term data about the impact of IBDoc® usage in clinical routine are beginning to emerge. Improving quality of life of IBD patients is extremely important, developing tools to allow patients to have

Allô docteurs is a French medical TV show, covering new topics every day to help patients dealing with their disease. On the 3rd of February 2020, the show was  about “living with IBD”. A 3 minute story was presented on how healthcare professionals and patients are using IBDoc®, the fecal calprotectin home test, to improve

New IBDoc® Tutorial Videos We created six new IBDoc® Portal Tutorial Videos. They help Healthcare Professionals that start using IBDoc® with the first steps of creating an account and setting up new users. Visit www.ibdoc.net for all Tutorial Videos Updated IBDoc® Flyer This flyer can be used to easily demonstrate the efficiency and practicality of IBDoc®. 

A very proactive patient in the UK suffering from Crohn`s disease wanted to share the story of his use of IBDoc® after one year. For the past 27 years, he tried every kind of medication available. Only a very strict diet based on rice, chicken and carrots associated with a therapeutic monoclonal antibody allowed him to

The Mercy University Hospital in Cork was the first hospital to introduce the BÜHLMANN IBDoc® self-testing in routine. After 4 years of use they can show the real benefit of IBDoc® for patients and the clinic. One of their most important finding was the number of unnecessary procedures avoided for patients. On a study of 131

At this years ECCO the ECCO IBD guidelines were updated to include a statement to use fecal calprotectin (fCAL) in IBD monitoring. This means that IBD patients will do many calprotectin measurements over their disease course. At the same time as in all chronic disease the therapy follow-up is more and more done remotely decreasing

Fecal calprotectin (fCAL) is a biomarker used for disease monitoring in patients suffering from intestinal bowel disease (IBD) since it correlates closely with mucosal healing. Calprotectin measuring requires patients to collect and return stool samples resulting in relatively low return rate of samples. Home-based fCAL testing may improve adherence. In this post three recent publications